In­nate Phar­ma moves on from a tri­al dis­as­ter with a €40M in-li­cens­ing pact with No­vo Nordisk

Just four months af­ter its lead ther­a­py lir­ilum­ab flunked a mid-stage test fight­ing acute myeloid leukemia, France’s In­nate Phar­ma has ex­changed a chunk of eq­ui­ty for a new im­muno-on­col­o­gy drug can­di­date from No­vo Nordisk.

The drug — which No­vo has test­ed in a pair of Phase I rheuma­toid arthri­tis stud­ies — is an an­ti-C5aR an­ti­body aimed at the “ac­cu­mu­la­tion and ac­ti­va­tion of myeloid-de­rived sup­pres­sor cells (MD­SC) and neu­trophils in the tu­mor mi­croen­vi­ron­ment.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.